Target intelligence / Profile preview

Coatomer subunit alpha (COPA)

Target
COPA
Molecular classification
Other (coatomer complex protein, vesicle trafficking protein), Endogenous ligand (xenin peptide), WD repeat domain-containing protein
01

Overview

Coatomer subunit alpha (COPA) is a core component of the coatomer complex I (COPI), a multi-protein complex essential for retrograde vesicular trafficking from the Golgi apparatus to the endoplasmic reticulum (ER) in eukaryotic cells[1][4][5]. COPA helps mediate intracellular protein sorting, Golgi structure, and maintenance of normal secretory pathway function. The COPA gene also gives rise to xenin, a gastrointestinal peptide hormone that regulates exocrine pancreatic secretion and intestinal motility[1][4][5]. Pathogenic mutations in COPA are linked to COPA syndrome, a rare disorder featuring autoimmunity, autoinflammation, and type I interferonopathy due to aberrant activation of the cGAS/STING signaling pathway[3]. Therapeutic intervention in COPA syndrome has included JAK1/2 inhibitors and experimental STING pathway inhibitors such as H-151[3]. Beyond inherited immune disorders, abnormal COPA transcript editing is implicated in certain cancers such as hepatocellular carcinoma[5]. COPA interacts within the COPI complex with other coatomer subunits (e.g., COPE, COPB1), and defects in related COPI proteins can cause additional developmental or immune pathologies[1][3]. No small-molecule drugs directly targeting COPA are clinically approved; current therapeutic approaches act on downstream pathways dysregulated as a consequence of COPA loss of function.

Other names
Coat protein complex I subunit alphaAlpha-COPHEP-COPCoatomer protein complex subunit alphaCOPI coat complex subunit alphaAlpha coat proteinProxeninXenin
02

Mechanism of action

Inhibition of inflammatory signaling (cGAS/STING pathway blockade), JAK-STAT pathway blockade (modulation of IFN signaling)

03

Biological functions

Intracellular vesicular transport (Golgi-ER)Structural maintenance of GolgiBiosynthetic protein transportSecretion regulation (via xenin peptide)Hormone activity (xenin)
04

Disease associations

Autoinflammation and immune dysregulation (COPA syndrome)Cancer (e.g., hepatocellular carcinoma)Other (rare genetic developmental and immune pathologies)
05

Safety considerations

Risk of excessive immune suppression with JAK inhibitorsPotential disruption of essential vesicular transportUnintended hormonal/gastrointestinal effects
06

Interacting drugs

H-151 (STING inhibitor, experimental for COPA syndrome)

2 more in the full profile.

07

Biomarkers

Type I interferon signatureISG gene expression (e.g., ISG15, IFIT1, MX1)Proinflammatory cytokines (IL6, TNF)

Beyond the preview

Go deeper on Coatomer subunit alpha (COPA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coatomer subunit alpha (COPA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call